EP Patent

EP2089359A2 — Mapk/erk kinase inhibitors

Assigned to Takeda Pharmaceutical Co Ltd · Expires 2009-08-19 · 17y expired

What this patent protects

Compounds, pharmaceutical compositions, kits and methods are provided for use with MEK that comprise a compound selected from the group consisting of wherein the variables are as defined herein.

USPTO Abstract

Compounds, pharmaceutical compositions, kits and methods are provided for use with MEK that comprise a compound selected from the group consisting of wherein the variables are as defined herein.

Drugs covered by this patent

cobimetinib-fumarate (COBIMETINIB FUMARATE)

Patent Metadata

Patent number: EP2089359A2
Jurisdiction: EP
Classification: —
Expires: 2009-08-19
Drug substance claim: No
Drug product claim: No
Assignee: Takeda Pharmaceutical Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.